Form 4 for JNJ Johnson & Johnson
Accepted 2026-08-18 18:31:06 ET · period of report 2026-08-17 · accession 0000200406-26-000175 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-18 18:31 | 2026-08-17 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $115.67 | +15.0K | 209.5K | +8% | +$1.74M |
| D | 2026-08-18 18:31 | 2026-08-17 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S - Sale+OE | $263.36 | -15.0K | 194.5K | -7% | -$3.95M |
| D | 2026-08-18 18:31 | 2026-08-17 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $0.00 | -15.0K | 28.7K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | M | A | 15,000 | $115.67 | 209,451.00 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-17 | S | D | 15,000 | $263.36 | 194,451.00 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Derivative | Employee Stock Options (Right to Buy) | 2026-08-17 | M | D | 15,000 | $0.00 | 28,712 | D | $115.67 · 2020-02-13 to 2027-02-13 | 15,000 Common Stock | (F2) Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |